These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32060511)

  • 1. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE; Morel CM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
    Morel CM; Lindahl O; Harbarth S; de Kraker MEA; Edwards S; Hollis A
    J Antibiot (Tokyo); 2020 Jul; 73(7):421-428. PubMed ID: 32203126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of hospital acquired infections and antimicrobial resistance in Europe: the way to go.
    Friedrich AW
    Wien Med Wochenschr; 2019 Feb; 169(Suppl 1):25-30. PubMed ID: 30623278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development.
    Theuretzbacher U; Årdal C; Harbarth S
    Infect Dis Rep; 2017 Mar; 9(1):6836. PubMed ID: 28458797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation.
    Årdal C; Lacotte Y; Edwards S; Ploy MC; On Behalf Of The European Union Joint Action On Antimicrobial Resistance And Healthcare-Associated Infections Eu-Jamrai
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34205554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where we are in the fight against Antimicrobial Resistance and Healthcare-Associated Infections. The opinion of the stakeholders of the European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI).
    Fabbro E; Arnau Sánchez J; Del Pilar López Acuña M; Hukelová H; Alcaraz Quiñonero M; Pantosti A; Busani L
    Ann Ist Super Sanita; 2022; 58(3):204-212. PubMed ID: 36128970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antibiotic restrictions: the pharmaceutical perspective.
    Power E
    Clin Microbiol Infect; 2006 Aug; 12 Suppl 5():25-34. PubMed ID: 16827822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic innovation for future public health needs.
    Theuretzbacher U
    Clin Microbiol Infect; 2017 Oct; 23(10):713-717. PubMed ID: 28652114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
    Brogan DM; Mossialos E
    Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS drug development in Europe--past progress and future challenges.
    Nutt DJ; Attridge J
    Neurobiol Dis; 2014 Jan; 61():6-20. PubMed ID: 23685094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections.
    Singer AC; Kirchhelle C; Roberts AP
    F1000Res; 2019; 8():238. PubMed ID: 30906539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.